Characteristics Predicting Short-Term and Long-Term Health-Related Quality of Life in Patients with Esophageal Cancer After Neoadjuvant Chemoradiotherapy and Esophagectomy.
Active surveillance
Esophageal cancer
Health-related quality of life
Neoadjuvant chemoradiotherapy
Journal
Annals of surgical oncology
ISSN: 1534-4681
Titre abrégé: Ann Surg Oncol
Pays: United States
ID NLM: 9420840
Informations de publication
Date de publication:
Dec 2023
Dec 2023
Historique:
received:
27
12
2022
accepted:
05
06
2023
medline:
8
11
2023
pubmed:
17
8
2023
entrez:
16
8
2023
Statut:
ppublish
Résumé
Esophagectomy is associated with lasting effect on health-related quality of life (HRQOL). Patients desire detailed information on the expected impact of treatment on their postoperative HRQOL. The aim of the present study is to identify clinicopathological characteristics predictive for changes in short-term and long-term HRQOL after neoadjuvant chemoradiotherapy (nCRT) and surgery. HRQOL was measured using EORTC-QLQ-C30 and QLQ-OES24 questionnaires prior to nCRT, three, six, nine and twelve months postoperatively and at a minimum of six years postoperatively. Based on previous experience and available literature, several subgroups were predefined for different clinicopathological characteristics: baseline global HRQOL, WHO performance status, histology, tumor stage and tumor location. The primary endpoints of the present study were the change compared to baseline in the HRQOL dimensions physical functioning and eating problems. Secondary endpoints were global HRQOL, fatigue and emotional problems. In total, 134 (76%) of 177 patients who received HRQOL questionnaires, responded at baseline. Patients who reported a high baseline global HRQOL had a more severe deterioration in eating problems (+14.5 to + 18.0), global HRQOL (-16.0 to -28.0) and fatigue (+10.5 to +14.9) up to six years postoperatively compared to patients who reported a low baseline global HRQOL. Patients who had stage 2 tumor (UICC 6th edition) had a more severe deterioration in eating problems (+14.6 to +19.0) and global HRQOL (-10.1 to -17.1) than patients who had stage 3 tumor. The results suggest that patients with locally advanced esophageal cancer in favorable condition at baseline decline more in terms of various HRQOL outcomes.
Sections du résumé
BACKGROUND
BACKGROUND
Esophagectomy is associated with lasting effect on health-related quality of life (HRQOL). Patients desire detailed information on the expected impact of treatment on their postoperative HRQOL. The aim of the present study is to identify clinicopathological characteristics predictive for changes in short-term and long-term HRQOL after neoadjuvant chemoradiotherapy (nCRT) and surgery.
METHODS
METHODS
HRQOL was measured using EORTC-QLQ-C30 and QLQ-OES24 questionnaires prior to nCRT, three, six, nine and twelve months postoperatively and at a minimum of six years postoperatively. Based on previous experience and available literature, several subgroups were predefined for different clinicopathological characteristics: baseline global HRQOL, WHO performance status, histology, tumor stage and tumor location. The primary endpoints of the present study were the change compared to baseline in the HRQOL dimensions physical functioning and eating problems. Secondary endpoints were global HRQOL, fatigue and emotional problems.
RESULTS
RESULTS
In total, 134 (76%) of 177 patients who received HRQOL questionnaires, responded at baseline. Patients who reported a high baseline global HRQOL had a more severe deterioration in eating problems (+14.5 to + 18.0), global HRQOL (-16.0 to -28.0) and fatigue (+10.5 to +14.9) up to six years postoperatively compared to patients who reported a low baseline global HRQOL. Patients who had stage 2 tumor (UICC 6th edition) had a more severe deterioration in eating problems (+14.6 to +19.0) and global HRQOL (-10.1 to -17.1) than patients who had stage 3 tumor.
CONCLUSIONS
CONCLUSIONS
The results suggest that patients with locally advanced esophageal cancer in favorable condition at baseline decline more in terms of various HRQOL outcomes.
Identifiants
pubmed: 37587357
doi: 10.1245/s10434-023-14028-8
pii: 10.1245/s10434-023-14028-8
pmc: PMC10625935
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
8192-8202Informations de copyright
© 2023. The Author(s).
Références
J Clin Oncol. 1998 Jan;16(1):139-44
pubmed: 9440735
Gut. 2001 Aug;49(2):227-30
pubmed: 11454799
J Gastrointest Surg. 2021 Jul;25(7):1657-1666
pubmed: 32909195
J Natl Cancer Inst. 1993 Mar 3;85(5):365-76
pubmed: 8433390
J Clin Oncol. 2020 Aug 10;38(23):2677-2694
pubmed: 32568633
Cancer. 2007 Aug 1;110(3):686-93
pubmed: 17582628
J Clin Oncol. 2018 Jan 20;36(3):268-275
pubmed: 29161204
Lancet Oncol. 2015 Sep;16(9):1090-1098
pubmed: 26254683
World J Gastroenterol. 2011 Nov 14;17(42):4660-74
pubmed: 22180708
N Engl J Med. 2012 May 31;366(22):2074-84
pubmed: 22646630
Ann Surg Oncol. 2010 Jan;17(1):23-30
pubmed: 19830496
Cancer. 2009 Sep 1;115(17):3868-78
pubmed: 19637245
BJU Int. 2014 Nov;114 Suppl 1:55-61
pubmed: 25070423
Dig Surg. 2019;36(6):462-469
pubmed: 30227434
Ann Surg. 2006 Feb;243(2):204-11
pubmed: 16432353
Dis Esophagus. 2020 Nov 18;33(11):
pubmed: 32444879
Value Health. 2015 Jan;18(1):110-5
pubmed: 25595241
Br J Cancer. 2008 Mar 11;98(5):888-93
pubmed: 18268490
Br J Surg. 2011 Aug;98(8):1124-31; discussion 1132
pubmed: 21674471
Eur J Cancer. 2003 Jul;39(10):1384-94
pubmed: 12826041
Br J Surg. 2008 Sep;95(9):1121-6
pubmed: 18581441
Ann Oncol. 2018 Feb 1;29(2):445-451
pubmed: 29126244
Ann Surg Oncol. 2008 Sep;15(9):2372-9
pubmed: 18626719
J Urol. 2018 Dec;200(6):1250-1255
pubmed: 29886089
J Clin Oncol. 2004 Oct 15;22(20):4202-8
pubmed: 15483031
BMJ. 2001 May 19;322(7296):1240-3
pubmed: 11358783
Ann Surg. 2022 Feb 1;275(2):e392-e400
pubmed: 32404661
BMC Cancer. 2018 Feb 6;18(1):142
pubmed: 29409469
Br J Surg. 2008 May;95(5):592-601
pubmed: 18300270
Best Pract Res Clin Gastroenterol. 2018 Oct - Dec;36-37:37-44
pubmed: 30551855
J Clin Oncol. 2018 Sep 20;36(27):2796-2803
pubmed: 30089078
J Clin Oncol. 2004 Jun 15;22(12):2395-403
pubmed: 15197201
J Clin Oncol. 2021 Jun 20;39(18):1995-2004
pubmed: 33891478
J Clin Oncol. 2009 Apr 20;27(12):1963-8
pubmed: 19289614
Ann Surg. 2019 Feb;269(2):291-298
pubmed: 29206677
Ann Surg. 2022 Mar 1;275(3):467-476
pubmed: 34191461
Stat Med. 1998 Mar 15-Apr 15;17(5-7):517-32
pubmed: 9549801
Soc Sci Med. 1992 Jul;35(2):139-45
pubmed: 1509303